A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Merck Sharp & Dohme Corp.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01472367
First received: November 11, 2011
Last updated: July 23, 2014
Last verified: July 2014

November 11, 2011
July 23, 2014
December 2011
December 2017   (final data collection date for primary outcome measure)
  • Change from baseline in Hemoglobin A1c (A1C) at Week 20 [ Time Frame: Baseline and Week 20 ] [ Designated as safety issue: No ]
  • Number of participants with adverse events [ Time Frame: 20 weeks ] [ Designated as safety issue: Yes ]
  • Number of participants who discontinued study drug due to an adverse event [ Time Frame: 20 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01472367 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)
A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus

The purpose of the study is to assess the safety of the addition of sitagliptin, and its effect on hemoglobin A1c (A1C), fasting plasma glucose (FPG) and the proportion of patients requiring glycemic rescue therapy in pediatric patients 10-17 years of age (inclusive) with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on metformin monotherapy.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: Metformin
    Metformin oral tablets twice daily. Participants on a metformin daily dose of 1000, 1250, or 1275 mg at screening will be switched to a metformin daily dose of 1000 mg (500 mg twice a day); 1500, 1700, or 1750 mg will be switched to a metformin daily dose of 1700 mg (850 mg twice a day); 2000 mg or more will be switched to a metformin daily dose of 2000 mg (1000 mg twice a day).
    Other Name: Glucophage
  • Drug: Sitagliptin + Metformin FDC
    Sitagliptin + metformin FDC oral tablet 50/500, 50/850, or 50/1000 mg dosed twice daily.
    Other Names:
    • MK-0431A
    • Janumet
  • Drug: Placebo to Metformin
    Matching placebo to metformin administered twice daily.
  • Drug: Placebo to Sitagliptin + Metformin FDC
    Matching placebo to sitagliptin + metformin FDC oral tablet administered twice daily.
  • Experimental: Sitagliptin + Metformin FDC
    Sitagliptin + Metformin fixed-dose combination (FDC) tablet 50/500, 50/850, or 50/1000 mg sitagliptin/metformin plus placebo to metformin twice daily for 20 weeks.
    Interventions:
    • Drug: Sitagliptin + Metformin FDC
    • Drug: Placebo to Metformin
  • Placebo Comparator: Placebo to Sitagliptin + Metformin FDC
    Placebo to sitagliptin + metformin FDC plus metformin 500, 850, or 1000 mg twice daily for 20 weeks.
    Interventions:
    • Drug: Metformin
    • Drug: Placebo to Sitagliptin + Metformin FDC
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
90
December 2017
December 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Has Type 2 Diabetes Mellitus (T2DM)
  • Has not received treatment with insulin for at least 12 weeks prior to the Screening Visit/Visit 1.
  • A1C greater than or equal to 6.5% and less than or equal to 10.0% on metformin, greater than or equal to 1500 mg/day, for greater than or equal to 12 weeks. NOTE: Participants on a daily dose of metformin greater than or equal to 1000 mg/day, but less than 1500 mg/day may be eligible if there is documentation that higher doses are not tolerated.
  • Between 10 and 17 years of age on day of signing informed consent with randomization to occur prior to 18th birthday.
  • Participant and a family member or adult closely involved in the daily activities will participate in the participant's treatment and study protocol (i.e., available for telephone calls, study visits and administration of study medication as needed).

Exclusion Criteria:

  • Known type 1 diabetes mellitus or documented evidence of positive diabetes auto-antibodies (if performed when participant was diagnosed with diabetes).
  • Known monogenic diabetes, secondary diabetes, or a genetic syndrome or disorder known to affect glucose tolerance other than diabetes.
  • Symptomatic hyperglycemia and/or moderate to large ketonuria requiring immediate initiation of another antihyperglycemic agent.
  • Participant has previously taken a dipeptidyl peptidase-IV (DPP-4) inhibitor (such as sitagliptin, vildagliptin, alogliptin, or saxagliptin) or glucagon-like peptide-1 (GLP-1) receptor agonist (such as exenatide or liraglutide).
  • Exhibits abnormal growth patterns or is being treated with growth hormone.
  • History of idiopathic acute pancreatitis or chronic pancreatitis.
Both
10 Years to 17 Years
No
Contact: Toll Free Number 1-888-577-8839
United States,   Argentina,   Bulgaria,   Canada,   Chile,   Colombia,   Dominican Republic,   Germany,   Guatemala,   Israel,   Italy,   Latvia,   Lithuania,   Malaysia,   Mexico,   New Zealand,   Romania,   Russian Federation,   Saudi Arabia,   Thailand,   United Arab Emirates,   United Kingdom
 
NCT01472367
0431A-170, CTRI/2012/09/003025
Yes
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP